The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Scientists have long-known that mRNA could hold the key to developing much-needed vaccines. The covid pandemic proved them right, spurring a boom in mRNA-based vaccine research that could soon ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.